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A B S T R A C T 
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: 
• To carry out a meta-analysis of identified studies to determine whether CBT leads to 
remission of 1) the primary child/ adolescent anxiety disorder and 2) all anxiety diagnoses, 
and/or 3) a clinically significant reduction in anxiety symptoms in comparison with passive 
(waiting list) controls, active controls, treatment as usual, or medication. 
• To determine the comparative efficacy of CBT alone, and the combination of CBT and 
medication, versus drug placebo. 
• To determine whether post-treatment gains of CBT are maintained at longer-term 
follow-up. 
• To describe the age range of participants included in CBT trials in order to determine 
the age of the youngest participants. 
• To determine whether CBT for anxiety leads to a clinically significant reduction in 
depressive symptoms, and/or improvements in global functioning. 
• To carry out subgroup analyses of different types of CBT according to 1) amount of 
therapist contact time; and 2) delivery format (child-focused individual, group, and 
with/without family involvement, and parent-delivered). 
• To carry out a subgroup analysis of CBT for children and adolescents with ASD and 
for children and adolescents with intellectual impairments. 
 B A C K G R O U N D 
Previous Cochrane Reviews (James 2005; James 2015) have shown that cognitive 
behavioural therapy (CBT), is effective in treating childhood anxiety disorders; however, 
questions remain regarding: 
• the relative efficacy of CBT versus non-CBT treatments; 
• the relative efficacy of CBT versus medication and the combination of CBT and 
medication versus placebo; 
• remission of the primary anxiety diagnosis and the proportion of children and 
adolescents who are free of all anxiety diagnoses after treatment; 
• the long-term effects of CBT; 
• the age of the youngest participants in trials of CBT for child and adolescent anxiety 
disorders; 
• benefits in relation to broader outcomes, including depressive symptoms and global 
functioning; 
• outcomes according to the amount of therapist contact time; 
• the efficacy of different delivery formats, including individual, group, with/without 
family involvement, and parent- delivered CBT. 
Description of the condition 
Anxiety disorders are amongst the most common psychiatric disorders, occurring in 6.5% of 
all children and adolescents (Polanczyk 2015). One of the diagnostic challenges in children 
and adolescents involves distinguishing normal, developmentally appropriate worries, fears 
and shyness from anxiety disorders. Distinguishing features of pathological anxiety include 
severity, persistence and associated impairment. An understanding of the developmental 
patterns of various anxieties is also important. School-age children commonly have worries 
about injury and natural events, whereas older children and adolescents typically have worries 
and fears related to school performance, social competence and health issues. The 
presentation of anxiety disorders varies with age. Young children can present with 
undifferentiated worries and fears and multiple somatic complaints - muscle tension, 
headaches or stomach aches - and sometimes angry outbursts. The latter may be mis- 
diagnosed as oppositional defiant disorder, as the child tries to avoid anxiety-provoking 
situations. Separation anxiety disorders are more common in younger children, than 
adolescents; and difficulties with social anxiety are typically associated with greater dis- 
turbance in adolescence (Waite 2014). Anxiety disorders with an onset in childhood often 
persist into adolescence (Last 1996), and early adulthood (Last 1997), and yet they often 
remain untreated, with an average delay of 9 to 23 years before anxiety disorders are first 
treated (Wang 2005). 
The International Classification of Diseases (ICD; WHO 1992), and Diagnostic and 
Statistical Manual (DSM; APA 2013), diagnostic systems distinguish various types of anxiety 
disorders, including generalised anxiety disorder, panic disorder, social anxiety disorder, 
separation anxiety disorder, agoraphobia, specific pho- bias, and selective mutism. These 
anxiety disorders are often associated with significant impairment in personal, social and aca- 
demic functioning (Pine 2009). Comorbidities are common and include depression (Kovacs 
1989), alcohol abuse (Kushner 1990), attention-deficit/hyperactivity disorder (ADHD), 
conduct disorder (Bittner 2007), suicidal behaviours and suicide (Hill 2011). Anxiety 
disorders in childhood and adolescence are also associated with adverse academic, health and 
social functioning in adulthood (Copeland 2014; Essau 2014). It is clear that anxiety 
disorders in this age group present serious ongoing health issues, and therefore, effective and 
readily accessible treatments are needed. 
Description of the intervention 
Current treatments for anxiety disorders in this age group include behavioural therapy, 
particularly for specific phobias, CBT or medication, or a combination of some or all these. 
NICE guidelines are available for the treatment of social anxiety disorder and recommend 
CBT that is specifically focused on social anxiety (NICE 2013). Indications for psychological 
treatment versus medication for other anxiety disorders are awaited, although given the 
prevalence of these disorders, the age of onset and public views on the acceptability of 
psychological treatments, these are often preferred as first-line therapy (Brown 2007; Young 
2006). CBT is a collaborative psychological treatment that can be delivered in various for- 
mats, individually or in groups, and with varying levels of parent or family involvement. 
One of the first manualised CBT programmes was Coping Cat (Kendall 1994), which 
consisted of psycho-education, modification of negative cognitions, exposure, social 
competence training, coping behaviour and self-reinforcement sessions. Others have 
followed, including the  Cool Kids programme,  the  Coping Koala programme (Barrett 
1996), Skills for Academic and Social Success (SASS) (Masia-Warner 2005), ACTION 
(Waters 2009), Intervention With Adolescents With Social Phobia (IAFS) (Sanchez-Garcia 
2009), the TAPS (Warner 2011), and Building Confidence programme (Galla 2012). 
Alternative programmes involve providing direct support to parents alone, guiding them to 
implement CBT strategies with their child (Guided Parent-Delivered CBT (GPD-CBT) 
(Lyneham 2006; Thirlwall 2013; Waters 2009). Some programmes have also been 
specifically adapted for children with autism spectrum disorders (ASDs), including the 
Multimodal Anxiety and Social Skills Intervention (MASSI) programme (White 2013), 
TAFF (Schneider 2011), Behavioural Interventions for Anxiety in Children with Autism 
(BIACA) (Wood 2009), and Facing Your Fears (FYF) (Reaven 2012). CBT programmes 
have been modified in various ways to make them appropriate for children with ASD, such as 
by including social stories, social coaching, visual aids and structured worksheets (Ung 
2015). 
How the intervention might work 
CBT for anxiety disorders in children and adolescents typically involves helping the child to 
firstly recognize anxious feelings and   
bodily or somatic reactions to anxiety, secondly, identify thoughts or cognitions in anxiety-
provoking situations (e.g. unrealistic or negative attributions and expectations), thirdly, 
modify these anxiety-provoking cognitions or develop coping skills (e.g. test out predictions 
based on anxious thoughts, modify anxious self-talk into coping self-talk, problem solving 
skills, social skills, relaxation training), and finally, evaluate outcomes. A key CBT procedure 
is exposure (Silverman 1996), which typically involves testing out and ‘facing’ fears in a 
gradually increasing hierarchy. Behavioural training strategies such as modelling and role 
playing are often applied. 
CBT for anxiety disorders in children and adolescents has traditionally begun with six to 
nine face-to-face sessions of anxiety management strategies (emotion identification, 
relaxation training, cognitive strategies), followed by exposure work (Barrett 1996; Kendall 
2006). In one meta-analysis (Reaven 2012), this traditional format of anxiety management 
sessions followed by expo- sure was observed in 93% of studies. However, Ale 2015 
found that treatment outcomes in CBT treatment trials for child and adolescent anxiety 
disorders were not related to the use of relaxation strategies or the timing of exposure work, 
and therefore suggested that relaxation training may not be an essential ingredient of CBT 
and it may not be necessary to delay exposure until after anxiety management sessions. 
Moreover, there is also some preliminary evidence that introducing exposure early in 
treatment, without any prior anxiety management sessions could improve outcomes while 
requiring fewer appointments (Whiteside 2015). Indeed, questions remain about the 
mechanism of change within CBT. Cognitive restructuring and exposure tasks have each 
been found to make substantial contributions to improvement in youth anxiety in line with 
CBT theory (Peris 2015). More time devoted to exposure has been linked to better 
outcomes, and greater time spent on more difficult exposure tasks predicted better 
outcomes (Peris 2017). Change in coping efficacy, but not anxious self-talk, has been found 
to mediate change in anxiety symptoms associated with CBT, medication (sertraline) and 
their combination, com- pared to placebo control (Kendall 2016). Furthermore, therapists’ 
ratings of child compliance and mastery also predict better out- comes (Peris 2017). 
Cognitive development also plays an important role, and while targeting behavioural 
avoidance appears crucial for children and adolescents, treatment that addresses 
interpretation biases may be particularly beneficial for adolescents, but less so for younger 
children (Waite 2015). 
CBT has been adapted to include family and parents in treatment sessions. The main 
aspects of CBT parent/family treatment guidelines involve firstly, modifying parents’ beliefs 
about ways to help their anxious child and assisting parents to help their child overcome 
anxious and avoidant behaviours, and secondly, assisting parents to manage their own 
anxiety. The mechanisms of change remain unclear and are possibly bi-directional. One 
study found child-focused anxiety treatments, regardless of intervention condition, resulted in 
improvements in non-targeted parent symptoms and family functioning, particularly when 
children responded successfully to treatment (Keeton 2013). Another study found fam- ilies 
with higher pre-treatment parental psychopathology showed more improvement in family 
functioning and caregiver strain, which in turn predicted greater youth anxiety reductions 
with treatment (Schleider 2015). 
It is generally assumed that CBT can be applied only after the child has reached a certain level 
of cognitive development. Kendall 1993 argued that the ability to measure a thought or belief 
against the notion of a rational standard and the ability to understand that a thought or belief 
can cause a person to behave and feel in a certain way were central to its proper use. The 
question arises: at what age does a child have the cognitive capacities to undertake these 
cognitive operations? One study (Hirshfeld-Becker 2010), reported positive effects in 
children younger than six years of age; however, it is not clear whether children younger than 
six years of age are able to use cognitive strategies included in traditional CBT protocols. In 
line with this, research suggests that young children may be more responsive to the 
behavioural than the cognitive elements of this approach (Essau 2004). With younger 
children, parental involvement appears particularly important. Recent work indicates that 
treatment of anxiety disorders in very young children may be effected by applying CBT 
principles through working directly with parents alone (Cartwright-Hatton 2011). Studies 
report positive outcomes for parent-only CBT for young children, but there are inconsistent 
findings in relation to whether child- parent delivery format is superior to parent-only or not 
(Monga 2015;  Waters 2009). 
Why it is important to do this review 
Anxiety disorders in children and adolescents represent a considerable source of morbidity 
and are associated with later adult psychopathology and greater economic burden than any 
other mental health disorder (Fineberg 2013). However, despite high prevalence and 
substantial morbidity, anxiety disorders in childhood and adolescence can be difficult to 
diagnose, and may be under recognised (NICE 2013) and, therefore, under-treated (Pine 
2009). It is widely reported that only a minority of children and adolescents with mental 
health problems receive treatment (Green 2004; Merikangas 2011), with particularly low rates 
of treatment access for anxiety disorders compared to behavioural disorders (Merikangas 
2011). Limited service provision represents a key barrier to treatment access (Reardon 2017), 
highlighting the importance of maximising the efficiency of treatment delivery to help ensure 
that effective treatment is more readily available to children and young people when they need 
it. 
The evidence base for treatment of anxiety in children and adolescents is growing. Initial 
trials of CBT were positive (Barrett 1996; Kendall 1994; Kendall 1997), and further 
randomised con- trolled trials (RCTs) and reviews followed. Several reviews suggest that 
CBT for anxiety disorders in this age group is effective (Ale 2015; Crowe 2017; James 
2015; Reynolds 2012; Silverman 2008), including an overview of systemic reviews 
(Bennett 2016). Overall there is a moderate response rate (e.g. 59%; James 2015); however, 
it has not been shown that CBT is superior to active controls or treatment as usual 
(Barrington 2005; James 2015; Southam-Gerow 2010). The effect sizes associated with 
CBT for childhood anxiety disorders do not differentiate it from attention placebo, 
although it is more effective than waiting list control (Ale 2015). 
This review will replace previous Cochrane Reviews of CBT for anxiety disorders in 
children and adolescents (James 2005; James 2015). The current review is to be 
undertaken to provide comprehensive and up-to-date evidence on the efficacy of CBT in 
the treatment of anxiety disorders in children and adolescents, including remission of all 
anxiety diagnoses, as well as the primary anxiety diagnosis, with varying amounts of 
therapist contact time and differing delivery formats, including individual, group, with/ 
without family/parent involvement, and parent-led. Further, this review will examine the 
efficacy of CBT relative to active treatments, such as educational support and treatment 
as usual. The question of the comparative efficacy of medication versus CBT and the 
combination of CBT and medication needs to be addressed. While it will not possible to 
determine the youngest age at which a child can benefit from CBT, this review will identify 
the age of the youngest participants in trials of CBT for child and adolescent anxiety 
disorders. Lastly, this review aims to assess whether treatment effects of CBT are 
maintained at long-term follow-up. It is recognised that children and adolescents with 
ASDs have high rates of anxiety disorders, particularly social anxiety disorder (Settipani 
2012); however, a review of CBT for anxiety disorders in ASD (Ung 2015), which included 
two open studies in a meta- analysis of 14 studies, found CBT to be effective in high-
functioning autism, and one recent RCT of CBT versus counselling found no difference 
in outcome (Murphy 2017). Furthermore, it is unclear how anxiety disorders are recognised 
or, indeed, treated in those with intellectual impairments, indicating a pressing need for 
work in this particular area. We will examine the efficacy of CBT in children and 
adolescents with ASD and those with intellectual impairments. 
Since the last Cochrane Review (James 2015), there have been several developments in the 
delivery of CBT for anxiety disorders. These include briefer or shorter interventions 
(including guided parent-delivered approaches, where therapists work with parents alone to 
support them to apply CBT principles with their child). Recent evidence suggests that children 
as young as two years old may benefit from parent-delivered CBT (Cartwright-Hatton 2011). 
’Briefer’ or ’shorter’ interventions refer not only to the number of sessions but the total 
duration of treatment. Due to the critical need for increased access to CBT for children with 
anxiety disorders, there are now a number of studies reporting successful treatment of anxiety 
disorders with shorter treatment protocols. 
Previous Cochrane Reviews (James 2005; James 2015) used a cut off of nine sessions of 
CBT, based on the practice and thinking at the time. 
CBT interventions delivered online or via digital devices (e.g. computerised CBT) have also 
been developed and are reviewed else- where (e.g. Pennant 2015). This review will 
therefore focus on face-to-face delivery models that include direct contact with either the 
child or parent alone, or the child and parent together. 
A further development is the issue of the reporting of remission of all anxiety diagnoses, as 
well as the primary anxiety diagnosis (Warwick 2016). Given the high level of comorbid 
anxiety disorders this is an important issue, but previously surprisingly over- looked. Indeed, 
focusing solely on recovery from the primary anxiety diagnosis means that children with 
comorbid anxiety disorders that are present following treatment are often still classed as 
‘recovered’. 
 
O B J E C T I V E S 
• To carry out a meta-analysis of identified studies to determine whether CBT leads to 
remission of 1) the primary child/adolescent anxiety disorder and 2) all anxiety diagnoses, 
and/or 3) a clinically significant reduction in anxiety symptoms in comparison with passive 
(waiting list) controls, active controls, treatment as usual, or  medication. 
• To determine the comparative efficacy of CBT alone, and the combination of CBT and 
medication, versus drug placebo. 
• To determine whether post-treatment gains of CBT are maintained at longer-term 
follow-up. 
• To describe the age range of participants included in CBT trials in order to determine 
the age of the youngest participants. 
• To determine whether CBT for anxiety leads to a clinically significant reduction in 
depressive symptoms, and/or improvements in global functioning. 
• To carry out subgroup analyses of different types of CBT according to 1) amount of 
therapist contact time; and 2) delivery format (child-focused individual, group, and 
with/without family involvement, and parent-delivered). 
• To carry out a subgroup analysis of CBT for children and adolescents with ASD and 
for children and adolescents with intellectual impairments. 
 
M E T H O D S 
 
Criteria for considering studies for this review 
 
Types of studies 
We will include RCTs, cross-over trials and cluster-randomised trials of manualised and 
modular CBT, involving direct contact with the child alone, the parent alone, or the child and 
the parent together, with comparators (waiting list, active controls, treatment as usual, 
medication or drug placebo). We will examine follow-up studies of these RCTs. 
Types of participants 
 
Participant characteristics 
Children and adolescents younger than 19 years. 
 
Diagnosis 
We will include participants meeting diagnostic criteria of the DSM (DSM III, III-R, IV, 
IV-TR, 5) (APA 1980; APA 1987; APA 1994; APA 2000; APA 2013), or of ICD 9 and 
ICD10 (WHO 1978; WHO 1992), for an anxiety disorder. Disorders classified as anxiety 
disorders vary across different versions of the DSM, and we will include participants meeting 
diagnostic criteria for one or more of the following disorders: generalised anxiety disorder or 
over-anxious disorder, separation anxiety disorder, social phobia or social anxiety disorder, 
panic disorder, agoraphobia, simple or specific phobias, or selective mutism. 
Comorbidity 
We will include all comorbidities allowable for anxiety disorders under the rules of DSM or 
ICD, such as ASD, intellectual impairment, depressive disorders, and physical disorders. 
Settings 
We will include all settings, such as research settings (i.e. university outpatient clinics, 
inpatient services, community clinics, and schools). 
Exclusion criteria 
We will exclude studies that only include participants with post- traumatic stress disorder 
or obsessive compulsive disorder, or both, as they are covered by separate Cochrane 
Reviews (Gillies 2016; O’Kearney 2006) and are no longer classified as ‘anxiety disorders’ in 
the DSM5 (APA 2013). 
Types of interventions 
 
Experimental intervention 
The intervention must be manualised CBT, or modular CBT, alone or in combination with 
medication and we require a documented, written protocol stating the specific treatment at 
each stage, provided by trained therapists under regular supervision. Since the last review 
(James 2015), where the number of sessions was arbitrarily fixed at nine, there are now 
several studies indicating that shorter treatment, in terms of number of sessions or dura- tion 
of sessions, or both, may be effective. We have therefore not included a minimum number of 
sessions or duration of sessions as a requirement. 
CBT has to be administered according to standard principles as a psychological model of 
treatment involving helping the child to recognise anxious feelings and somatic reactions to 
anxiety; identify cognitions in anxiety-provoking situations; modify these anxiety-provoking 
cognitions, and respond to behavioural training strategies with exposure in vivo or by 
imagination, often in a gradual, hierarchical manner. 
CBT can be delivered to children (child-focused) or to parents alone (parent-delivered). In 
child-focused CBT, the child has direct face-to-face contact with a therapist. Child-focused 
CBT can be delivered individually, in a group format or with family or parental involvement. 
The latter spans a range of direct involvement, such as (rarely), the whole family and (more 
usually), the parents for some conjoint or separate sessions. CBT with family/parental in- 
volvement may include providing psycho-education for parents or teaching parents to be co-
therapists. Parent-delivered CBT only involves direct face-to-face contact with parents and 
provides sup- port for parents to help them to implement CBT strategies in their child’s day-
to-day life. Parent-delivered CBT can be delivered individually or in a group format. We will 
not include CBT interventions delivered online or via digital devices (e.g. computerised 
CBT). 
The control groups are to be waiting list or active non-CBT treatment, or medication for the 
treatment of anxiety (e.g. selective serotonin-reuptake inhibitors (SSRIs)), or drug placebo. 
The comparison of CBT against waiting list yields a baseline or estimate of CBT versus no 
treatment, whereas comparison of alternative active therapies and medication against CBT 
allows one to demonstrate any added effect or not of CBT over other active therapies and 
medication. 
Where CBT is delivered in combination with medication for the treatment of anxiety, the 
control group is to be drug placebo. 
Where studies include medication for the treatment of anxiety (in combination with CBT or 
alone), no concurrent medication for the treatment of anxiety is to be administered 
naturalistically. Where studies do not include medication for the treatment of anxiety, any 
medications administered naturistically need to be stable before and during the study. 
Comparator interventions 
• Waiting list and no treatment for anxiety during that period 
• Psychological treatment that did not include CBT elements, or attention only (e.g. 
support but with no elements of CBT) 
• Treatment  as usual 
• Medication for the treatment of anxiety 
• Drug placebo 
 
Types of outcome measures 
 
Primary outcomes 
We will include studies that meet the above inclusion criteria regardless of whether they 
report on the following outcomes. 
• Remission: the absence of the primary diagnosis of an anxiety disorder post-treatment, 
made by reliable and valid structured interviews for DSM or ICD child and adolescent 
anxiety disorders, including: 
◦ Anxiety Disorder Interview Schedule for Children - Child and Parent (ADIS-C/P) 
(Silverman 1987) 
◦ Anxiety Disorder Interview Schedule for Children - Child (ADIS-C) (Silverman  
1987) 
◦ Anxiety Disorder Interview Schedule for Children - Parent (ADIS-P) (Silverman  
1987) 
◦ Diagnostic Interview Schedule for Children, Adolescents and Parents (DISCAP) 
(Holland  1995) 
The diagnostic interviews must be carried out independently of the treatment team. 
• We will determine acceptability by the numbers of participants who were lost to the 
post-treatment assessment. 
 
Secondary outcomes 
• Remission: defined as the absence of all diagnoses of an anxiety disorder post-
treatment, made by reliable and valid structured interviews for DSM or ICD child and 
adolescent anxiety disorders. 
• Adverse events: we will determine adverse events outcomes by the number and type of 
reported adverse events during the trial from randomisation to post-treatment assessment 
(e.g. deterioration in anxiety symptoms, deterioration in global functioning, rates of self-
harm, suicide attempts). 
• Reduction in anxiety symptoms post-treatment: to be measured using psychometrically 
robust measures of anxiety symptoms (Myers 2002), that yield symptom scores on 
continuous scales, such as: 
◦ Screen for Child Anxiety Related Emotional Disorders (SCARED) (Birmaher1999); 
◦ Spence Children’s Anxiety Scale (SCAS) (Spence1997); 
     ◦ Revised Children’s Anxiety and Depression Scale (RCADS) - Anxiety Scale 
(Chorpita 2000); 
     ◦ Revised Children’s Manifest Anxiety Scale (RCMAS) (Reynolds 1985); 
     ◦ Multidimensional Anxiety Scale for Children (MASC) (March 1997); 
     ◦ Child Behaviour Checklist (CBCL) - Internalising scale (Achenbach 1991); 
     ◦ State-Trait Anxiety Inventory for Children (STAI-C) (Spielberger 1973); 
     ◦ Social Phobia and Anxiety Inventory for Children (SPAI-C) (Beidel 1995). 
     ◦ Social Anxiety Scale for Adolescents (SAS-A) (La Greca 1998). 
These scales are self-reported or are completed by a parent or guardian or an independent 
rater. Multiple reporters are often used, but the reliability of each reporter is likely to vary 
with the child’s age (Evans 2017). We will therefore determine reduction in anxiety 
symptoms separately for 1) self-reported and 2) parent- reported or independent rater, or 
both. Often multiple measures are also reported, and we will include the most validated, best 
recognised, or most frequently used measures in the analysis. 
A crucial issue is how well these measures discriminate between clinical and non-clinical 
levels of anxiety. We will prioritise symptom measures that are closely aligned with 
diagnostic categories, with strong discriminant validity (e.g. RCADS, SCAS, SCARED). 
• Reduction in depressive symptoms post-treatment: to be measured using 
psychometrically robust measures of depressive symptoms that yield symptom scores on 
continuous scales, such as: 
◦ Children’s Depression Inventory (Kovacs 1989); 
◦ Beck Depression Inventory (Beck 1996); 
◦ Revised Children’s Anxiety and Depression Scale (RCADS) - Depression Scale 
(Chorpita 2000); 
◦ Mood and Feelings Questionnaire (Angold 1995). 
These measures may be self-reported, or completed by a parent or independent rater, or both. 
If multiple depressive symptom measures/reporters are used, we will include the most 
validated, best recognised or most frequently used measures in the analysis. 
• Improvement in global functioning post-treatment: to be measured using 
psychometrically robust measures of global functioning that yield symptom scores on 
continuous scales, such as: 
◦ Children’s Global Assessment Scale (CGAS) (Shaffer 1983). 
These measures may be self-reported or completed by a parent or independent rater, or both. 
If multiple global functioning measures/reporters are used, we will include the most 
validated, best recognised or most frequently used measures in the analysis. 
• Remission defined by the absence of the primary anxiety disorder diagnosis at a series 
of long-term follow-up time points 
(≤ 6 months post-treatment, > 6 months post-treatment and ≤ 
12 months post-treatment, and > 12 months post-treatment). 
• Remission defined as the absence of all diagnoses of an anxiety disorder at a series of 
long-term follow-up time points (≤ 6 months post-treatment, > 6 months post-treatment and ≤ 
12 months post-treatment, and >12 months post-treatment). 
• Reduction in anxiety symptoms at a series of long-term follow-up time points (≤ 6 
months post-treatment, > 6 months post-treatment and ≤ 12 months post-treatment, and > 12 
months post-treatment). 
 
Search methods for identification of studies 
For the previous published version of this review, we identified eligible studies (RCTs) of 
CBT for anxiety disorders in children and adolescents from the Cochrane Common Mental 
Disorders Controlled Trials Register (CCMDCTR; most recent search, 1 May 2012; 
Appendix 1). 
 
Electronic searches 
For this update we will run searches on the following databases using relevant keywords, 
subject headings (controlled vocabularies) and search syntax, appropriate to each resource: 
• CCMDCTR (May 2012 to June 2016; Appendix 1); 
• Cochrane Central Register of Controlled Trials (CENTRAL; current year and issue). 
• Ovid MEDLINE (2012 onwards; Appendix 2); 
• Ovid Embase (2012 onwards); 
• Ovid PsycINFO (2012 onwards) 
There will be no restriction on language or publication status applied to the searches. 
We will also search the international trials registries (including ClinicalTrials.gov and the 
WHO International Clinical Trials Registry Platform (ICTRP)) to identify additional ongoing 
and un- published studies. 
 
Searching other resources 
 
Grey literature 
We will search the grey literature for dissertations and theses: 
• Electronic Theses Online Service (EThOS) - British Library ethos.bl.uk/Home.do 
• DART - Europe e-theses Portal www.dart-europe.eu/basic- search.php 
• Networked Digital Library of Theses and Dissertations (NDLTD) search.ndltd.org/ 
• PQDT Open - open access dissertations and theses 
pqdtopen.proquest.com/search.html 
• Proquest Dissertations & Theses Global search.proquest.com/pqdtglobal/dissertations/ 
 
Reference lists 
We will check the reference lists of all included studies and relevant systematic reviews to 
identify additional studies missed from the original electronic searches (for example 
unpublished or in-press citations). 
 
Correspondence 
We will contact study authors and subject experts for information on unpublished or ongoing 
studies, or to request additional data. 
 
Data collection and analysis 
 
Selection of studies 
Two review authors (AJ, TR), will independently screen titles and abstracts for inclusion of 
all the potential studies we identify as a result of the search and code them as ‘retrieve’ 
(eligible or potentially eligible/unclear) or ‘do not retrieve’. We will retrieve the full-text 
study reports/publications, and two review authors (AJ, TR), will independently screen the 
full texts to identify studies for inclusion, and identify and record reasons for exclusion of the 
ineligible studies. We will resolve any disagreement through discussion or, if required, we 
will consult a third person (GJ, CC). We will identify and exclude duplicate records and we 
will collate multiple reports that relate to the same study so that each study rather than each 
report is the unit of interest in the review. We will record the selection process in sufficient 
detail to complete a PRISMA flow diagram (Moher 2015), and ‘Characteristics of excluded 
studies’ table. 
 
Data extraction and management 
We will use a data collection form to extract study characteristics and outcome data, which 
we will pilot on at least one study in the review. Two review authors (AJ, TR) will extract 
study character- istics and outcome data from included studies. We will extract the following 
study characteristics. 
• Methods: study design, total duration of study, details of any ‘run-in’ period, number 
of study centres and location, study setting, withdrawals, and date of study 
• Participants: number, mean age, age range, gender, severity of condition, diagnostic 
criteria, comorbid conditions, inclusion criteria, and exclusion criteria 
• Interventions: intervention, comparison, concomitant medications, excluded 
medications, delivery format, therapist contact time, who delivers intervention 
• Outcomes: primary and secondary outcomes specified and collected, and time points 
reported 
• Notes: funding for study, and notable conflicts of interest of study authors 
We will note in the ‘Characteristics of included studies’ table if outcome data were not 
reported in a usable way. We will resolve disagreements by consensus or by involving a third 
person (GJ, CC). One review author (AJ), will transfer data into the Review Manager 5 file 
(Review Manager 2014). We will double-check that data are entered correctly by comparing 
the data presented in the systematic review with the study reports. A second review author 
(TR), will spot-check study characteristics for accuracy against the study report. 
 
Main comparisons 
• CBT compared with waiting list and no treatment controls 
• CBT compared with other active treatments 
• CBT compared with treatment as usual 
• CBT compared with medication or placebo 
• CBT and medication combination compared with placebo 
 
Assessment of risk of bias in included studies 
Two review authors (AJ, TR), will independently assess risk of bias for each study using the 
criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 
2017). We will resolve any disagreements by discussion or by involving another author (GJ, 
CC). We will assess the risk of bias according to the following domains. 
• Random sequence generation 
• Allocation concealment 
• Blinding of participants and personnel 
• Blinding of outcome assessment 
• Incomplete outcome data 
• Selective outcome reporting 
• Other bias 
We will judge each potential source of bias as high, low or unclear and provide a supporting 
quotation from the study report together with a justification for our judgment in the ‘Risk of 
bias’ table. We will summarise the risk of bias judgements across different studies for each of 
the domains listed. 
We will identify selection bias by assessing the adequacy of the randomisation process in 
terms of the description of adequacy of sequence generation and the concealment of 
treatment group al- location. Given the nature of psychological interventions, blind- ing of 
either participants or personnel delivering the treatments will only be possible in those studies 
involving CBT versus active controls or treatment as usual; therefore, we will only be able to 
assess performance bias in those studies. We will assess detection bias by identifying whether 
study personnel carrying out outcome assessments were blinded to the treatment status of 
participants. We will assess attrition bias by determining whether studies pro- vide a 
description of withdrawals and drop-outs. 
We will not exclude studies from meta-analysis on the basis of the ‘Risk of bias’ assessment. 
We will conduct sensitivity analyses for the primary outcome, excluding trials with ‘high’ or 
‘unclear’ risk of bias ratings for allocation concealment if appropriate. We will report the 
remainder of the ‘Risk of bias’ assessments for these trials, and include discussion of this 
assessment in the Results and Discussion sections. 
 Measures of treatment effect 
To assess post-treatment outcomes, we will use dichotomous data on remission of primary 
anxiety diagnosis and all anxiety diagnoses; and continuous data on anxiety symptoms, 
depressive symptoms and global functioning, with the use of standardised measures. We will 
use data from the assessment administered immediately after treatment (or where there are 
multiple time points, the assessment closest to the end of treatment) to assess post- treatment 
outcomes. We will also use these measures to assess the maintenance of treatment effects 
versus waiting list controls, active controls, medication, and drug placebo at a series of 
follow- up time points (≤ 6 months post-treatment, > 6 months  post-treatment and ≤ 12 
months post-treatment, and > 12 months post-treatment). Where studies report follow-up data 
at multiple 
time points within one category (e.g. 1-month and 3-month follow-up), we will use data from 
the longer follow-up period. To assess acceptability, we will use frequency data on the 
numbers of participants who were lost to post-treatment assessment. Ad- verse events will be 
determined by the number and type of adverse events during the trial, from randomisation to 
the post-treatment assessment. 
Primary outcomes will include: remission of the primary anxiety diagnosis at the post-
treatment assessment, and the number (and %) of participants lost to the post-treatment 
assessment (accept- ability). 
 
Dichotomous data 
We will analyse dichotomous data as odds ratios (OR) and 95% confidence intervals (CI). 
Continuous data 
We will analyse continuous data as mean difference (MD) or standardised mean difference 
(SMD). We will enter data presented as a scale with a consistent direction of effect. 
We will narratively describe skewed data reported as medians and interquartile ranges. 
 Unit of analysis issues 
 
Cluster-randomised trials 
We will include cluster-randomised controlled trials based in schools. Cluster-randomised 
trials may, in principle, be combined with individually randomised trials in the same meta-
analysis (Deeks 2017). We do not anticipate that there would be many cluster-randomised 
trials; therefore, we will include identified cluster-randomised trials in the meta-analyses and 
sensitivity analyses that we plan to undertake to investigate the robustness of any conclusions 
that we draw. To correct the influence of any cluster trials, we will use an average intra-class 
correlation coefficient of 0.02 (Health Services Research Unit 2004). 
The effective sample size of a single intervention group in a cluster- randomised trial is its 
original sample size divided by the ‘design effect’. The design effect is 1 + (M - 1) ICC, 
where M is the average cluster size and ICC is the intra-cluster correlation coefficient (Rao 
1992). For dichotomous data, we will divide both the number of participants and the number 
experiencing the event by the same design effect. For continuous data, only the sample size 
will be reduced; we will not alter means and standard deviations. 
Cross-over trials 
We do not anticipate that there will be many cross-over trials, and the data required to include 
a paired analysis in a meta-analysis is often not reported (Higgins 2011). We will therefore 
include any identified cross-over trials in the meta-analysis, but only include data from the 
first trial period (i.e. prior to the ‘ross-over’). 
Studies with multiple treatment groups 
Where multiple trial arms are reported in a single trial, we will include only the relevant 
arms. Studies with more than two intervention arms can pose analytical problems in pair-wise 
meta- analysis. Where studies have two or more relevant active treatment arms to be 
compared against controls, we will manage data in this review as follows. 
Continuous data 
We will divide the control group equally into two or more groups we will compare the means 
and SDs of these groups against the means and SDs of the two treatment arms. 
Dichotomous data 
For trials with two or more active treatment arms and a control group, we will split 
participants in the control-arm group equally between the active treatment arms. 
Dealing with missing data 
We will contact investigators or study sponsors in order to verify key study characteristics 
and obtain missing numerical outcome data where possible (e.g. when we identify a study as 
abstract only). We will document all correspondence with study authors and report which 
study authors responded in the full review. 
Missing statistics 
In the first instance, we will attempt to contact the original re- searchers for any missing data. 
If the study only report standard errors (SEs), we will calculate standard deviations (SDs). 
Missing participants 
We will undertake intention-to-treat (ITT) analyses. For the analysis of dichotomous data, we 
will assume that all non-completers in the CBT group are treatment failures and non-
completers in the control group are treatment successes, thereby yielding the most 
conservative treatment estimate. We will not perform last observation carried forward 
(LOCF) analysis for symptoms, as we will not have access to raw data. 
Assessment of heterogeneity 
We will assess clinical heterogeneity by comparing differences in the distribution of 
important participant factors between studies (e.g. age, gender, specific diagnosis, duration 
and severity of disorder, associated comorbidities). We will assess methodological 
heterogeneity by comparing trial factors (randomisation, concealment, blinding of outcome 
assessment, losses to follow-up). We will use the Chi2 test (Deeks 2017), and the I2 statistic 
(Higgins 2003), to assess heterogeneity. We will set significance at P < 0.1. The Cochrane 
Handbook for Systematic Reviews of Interventions (Deeks 2017) recommends using a range 
for the I2 statistic and a guide to interpretation. For this review, if we find either moderate 
heterogeneity (I2 statistic in the range of 30% to 60%) or substantial heterogeneity (I2 
statistic in the range of 60% to 90%), we will use subgroup and sensitivity analyses, with 
meta-regression analyses (STATA 2012). 
Assessment of reporting biases 
Where a minimum number of 10 studies are included, we will investigate publication bias 
using funnel plots (Sterne 2017), and we will subject any asymmetry found to statistical 
investigation using Egger’s test (STATA 2012). 
Data synthesis 
We will undertake meta-analyses only where this is meaningful, that is, if the treatments, 
participants and the underlying clinical question are similar enough for pooling to make 
sense. We will undertake ITT and completer analyses. 
We will carry out separate analyses to identify whether post-treatment, CBT is more effective 
than waiting list control and other active treatments, with subgroups of active controls and 
treatment as usual; and medication; and drug placebo; and also to identify whether CBT in 
combination with medication is more effective than drug placebo. 
We will use follow-up data for each comparison to assess maintenance of treatment gains. If 
it is meaningful to do so, we will pool data separately for each follow-up time point (≤ 6 
months post- treatment, > 6 months post-treatment and ≤ 12 months post- treatment, and > 12 
months post-treatment). Where studies report follow-up data at multiple time points within 
one category (e.g. 9-month and 12-month follow-up), we will include data from the longer 
follow-up period. 
Dichotomous data 
The review will use ORs and 95% CIs based on the random-effects model, with pooling of 
data via the inverse variance method of weighting. We will set significance at P < 0.05. 
Where available, we will use combined data from an interview with the child or adolescent 
and the parent; otherwise we will use data from one interview (child/adolescent or parent 
interview). We will calculate the number needed to treat for an additional beneficial outcome 
(NNTB) with 95% CIs (STATA 2012). We will calculate a summary statistic of all those 
responding to treatment as a percentage of the total number of participants for each 
comparison. 
Continuous data 
We will conduct analysis of continuous data, based on the random-effects model, with 
pooling of data via the inverse variance method of weighting. We will use the SMD to pool 
continuous data, measured in different ways across studies but conceptually the same (i.e. 
measuring anxiety or depressive symptoms or global functioning). For continuous data 
measuring anxiety symptoms, we will pool child/adolescent report and parental/clinician 
reports separately. Where both endpoint and change data are available for the same outcome, 
we will present the endpoint. We will set significance at P < 0.05. 
Tables and figures 
We will enter data into Review Manager 5 (Review Manager 2014), and present them 
graphically, so that the area to the left of the line of no effect indicates a favourable outcome 
for CBT. We will use tables to display characteristics of the studies included. We will present 
excluded studies in a table with reasons for exclusion. We will summarise the risk of bias in 
the included studies in a Figure, and will include a PRISMA flow chart (Moher 2015). 
Subgroup analysis and investigation of heterogeneity 
The critical need to improve access to treatment for child anxiety disorders means that it is 
particularly important to explore the efficacy of approaches that may help maximise 
treatment efficiency, including alternative delivery formats and briefer interventions that 
involve less therapist contact time than traditional approaches. As outlined above, there are 
also unanswered questions in relation to the benefits of CBT for children and adolescents 
with ASD and intellectual impairments. We will therefore explore the efficacy of different 
delivery formats, the efficacy of briefer and shorter interventions, and examine treatment 
effects among children and adolescents with ASD and those with intellectual impairment 
using subgroup analyses. Specifically, we will undertake subgroup analyses to examine 
differences between: 
• different delivery formats, including child-focused (individual, group, and 
family/parental involvement) and parent- delivered; 
• interventions with varying amount of therapist contact time (< 6 hours, 6 to 10 hours, 
10 to 20 hours, > 20 hours); 
• children and adolescents with and without  ASDs; 
• children and adolescents with and without intellectual impairments. 
We will assess statistical heterogeneity for all analyses and between groups with the Chi2 test 
and the I2 statistic and we will set significance at P < 0.1. 
Sensitivity analysis 
Sensitivity analysis is the study of how the uncertainty in the out- put of an analysis can be 
apportioned to different sources of uncertainty in its inputs. Sensitivity analyses can, 
therefore, be carried out to test the robustness of decisions made in the review process. We 
will carry out sensitivity analyses where there is evidence of the following: 
• significant heterogeneity: we will inspect forest plots and examine each study in turn 
to determine the source of any significant heterogeneity; 
• selection bias: we will exclude those studies judged to be at high risk of selection bias 
from the main analysis; 
• allocation concealment: we will exclude from the main analysis those studies judged 
to be at high risk of bias for allocation concealment. 
We will undertake all of the above sensitivity analyses for the ITT and the completer 
analyses. 
 
GRADE and ‘Summary of findings’ table 
We will create a ‘Summary of findings’ table including the follow- ing primary outcomes: 
• remission of primary anxiety diagnosis post-treatment; 
• acceptability in terms of drop-outs from randomisation to the post-treatment 
assessment; 
and the following secondary outcomes: 
• remission of all anxiety diagnoses post-treatment; 
• adverse events from randomisation to the post-treatment assessment; 
• reduction in anxiety symptoms (self-reported and parent- reported) post-treatment; 
• reduction in depressive symptoms post-treatment; 
• improvement in global functioning post-treatment. 
We will use the five GRADE considerations (study limitations, consistency of effect, 
imprecision, indirectness and publication bias) to assess the quality of a body of evidence as 
it relates to the studies that contribute data to the meta-analyses for the pre-specified primary 
and secondary outcomes. Two review authors (AJ, TR), will independently assess risk of 
bias, and in case of disagreement will seek consensus between four review authors (AJ, TR, 
GJ, CC). We will use the methods and recommendations described in Section 8.5 (Higgins 
2017), and Chapter 12 (Schünemann 2017), of the Cochrane Handbook for Systematic 
Reviews of Interventions, and using GRADEpro software (GRADEpro GDT 2015). We will 
justify all decisions to downgrade or upgrade the quality of studies using footnotes and make 
comments to aid the reader’s under- standing of the review where necessary. We will 
consider whether there is any additional outcome information that we were unable to 
incorporate into the meta-analyses, note this in the comments and state if it supports or 
contradicts the information from the meta-analyses. 
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A P P E N D I C E S 
 
 
Appendix1. Cochrane Common Mental Disorders Controlled Trials Register 
(CCMDCTR) 
 
Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR) 
Cochrane Common Mental Disorders (CCMD) maintains two archived clinical trials 
registers at its editorial base in York, UK: a references register and a studies-based register. 
The CCMDCTR-References Register contains over 40,000 reports of RCTs in depression, 
anxiety and neurosis. Approximately 50% of these references have been tagged to 
individual, coded trials. The coded trials are held in the CCMDCTR-Studies Register and 
records are linked between the two registers through the use of unique Study ID tags. 
Coding of trials is based on the EU-Psi coding manual, using a controlled vocabulary; ( 
please contact the CCMD Information Specialists for further details). Reports of trials for 
inclusion in the Group’s registers are collated from routine ( weekly), generic searches of 
MEDLINE ( 1950 to 2016), Embase ( 1974 to 2016) and PsycINFO ( 1967 to 2016); 
quarterly searches of the Cochrane Central Register of Controlled Trials ( CENTRAL) and 
review-specific searches of additional databases. Reports of trials are also sourced from 
international trial registers via the World Health Organization’s trials portal ( the 
International  Clinical Trials Registry Platform ( ICTRP)), pharmaceutical companies, the 
hand searching of key journals, conference proceedings and other (non-Cochrane) 
systematic reviews and meta-analyses. 
Details of CCMD’s generic search strategies (used to identify RCTs) can be found on the 
Group’s website, ( cmd.cochrane.org/ specialised-register), with an example of the core 
MEDLINE search (used to inform the register) listed below. The Group’s Specialised Register 
has fallen out of date with the Editorial Group’s move from Bristol to York in the summer of 
2016. 
Core search strategy used to inform the Cochrane Common Mental Disorders Group’s 
Specialised Register: OVID MEDLINE (to June 2016) 
A weekly search alert based on condition + RCT filter only 
1. [MeSH Headings]: 
eating disorders/ or anorexia nervosa/ or binge-eating disorder/ or bulimia nervosa/ or 
female athlete triad syndrome/ or pica/ or hyperphagia/ or bulimia/ or self-injurious 
behavior/ or self mutilation/ or suicide/ or suicidal ideation/ or suicide, attempted/ or 
mood disorders/ or affective disorders, psychotic/ or bipolar disorder/ or cyclothymic 
disorder/ or depressive disorder/ or depression, postpartum/ or depressive disorder, major/ 
or depressive disorder, treatment-resistant/ or dysthymic disorder/ or seasonal affective 
disorder/ or neurotic disorders/ or depression/ or adjustment disorders/ or exp antidepressive 
agents/ or anxiety disorders/ or agoraphobia/ or neurocirculatory asthenia/ or obsessive-
compulsive disorder/ or obsessive hoarding/ or panic disorder/ or phobic disorders/ or stress 
disorders, traumatic/ or combat disorders/ or stress disorders, post-traumatic/ or stress 
disorders, traumatic, acute/ or anxiety/ or anxiety, castration/ or koro/ or anxiety, separation/ 
or panic/ or exp anti-anxiety agents/ or somatoform disorders/ or body dysmorphic 
disorders/ or conversion disorder/ or hypochondriasis/ or neurasthenia/ or hysteria/ or 
munchausen syndrome by proxy/ or munchausen syndrome/or fatigue syndrome, chronic/ 
or obsessive behavior/ or compulsive behavior/ or behavior, addictive/ or impulse control 
disorders/ or firesetting behavior/ or gambling/ or trichotillomania/ or stress, 
psychological/ or burnout, professional/ or sexual dysfunctions, psychological/ or 
vaginismus/ or Anhedonia/ or Affective Symptoms/ or *Mental Disorders/ 
2. [Title/ Author Keywords]: 
(eating disorder* or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or 
mutilat*)) or suicide* or suicidal or parasuicid* or mood disorder* or affective disorder* or 
bipolar i or bipolar ii or (bipolar and (affective or disorder*)) or mania or manic or 
cyclothymic* or depression or depressive or dysthymi* or neurotic or neurosis or 
adjustment disorder* or antidepress* or anxiety disorder* or agoraphobia or obsess* or 
compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or 
somatoform or somati# ation or medical* unexplained or body dysmorphi* or conversion 
disorder or hypochondria* or neurastheni* or hysteria or munchausen or chronic fatigue* or 
gambling or trichotillomania or vaginismus or anhedoni* or affective symptoms or mental 
disorder* or mental health).ti,kf. 
3. [RCT filter]: 
(controlled clinical trial.pt. or randomized controlled trial.pt. or (randomi#ed or 
randomi#ation).ab,ti. or randomly.ab. or (random* adj3 (administ* or allocat* or assign* 
or class* or control* or determine* or divide* or distribut* or expose* or fashion or 
number* or place* or recruit* or subsitut* or treat*)).ab. or placebo*.ab,ti. or drug 
therapy.fs. or trial.ab,ti. or groups.ab. or (control* adj3 (trial* or study or studies)).ab,ti. or 
((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or dummy*)).mp. or clinical 
trial, phase ii/ or clinical trial, phase iii/ or clinical trial, phase iv/ or randomized controlled 
trial/ or pragmatic clinical trial/ or (quasi adj (experimental or random*)).ti,ab. or 
((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group)).ab.) 
4. (1 and 2 and 3) 
Records are screened for reports of RCTs within the scope of the Cochrane Common 
Mental Disorders Group. Secondary reports of RCTs are tagged to the appropriate study 
record. 
Similar weekly search alerts are also conducted on OVID Embase and PsycINFO, using 
relevant subject headings (controlled vocabularies) and search syntax, appropriate to each 
resource. 
The CCMDCTR was search for the previously published version of this review using the 
following terms: CCMDCTR-Studies: 
Condition = (anxiety or anxious or “phobic disorder*“ or “panic disorder*” or “social phobia”) 
AND 
Intervention = (behavior* or behaviour* or cognitive*) AND 
Age = (child* or adolescent* or unclear or “not stated”) 
CCMDCTR-References was searched using a more sensitive set of free-text terms to 
identify additional untagged/uncoded reports of RCTs: 
(CBT or cognitive* or behavior* or behaviour*) and (anxiety or anxious or *phobi* or 
panic*) and (child* or adolesc* or juvenil* or school* or pediatri* or paediatri* or teen* or 
young or youth*). 
We will update the search of the CCMDCTR to June 2016. 
 
Appendix 2. Update search (MEDLINE) (2012-2018) 
In addition to searching the CCMDCTR we will run searches on Ovid MEDLINE, 
Embase, PsycINFO and CENTRAL. The MEDLINE search is displayed below, we will 
map this across to the other databases, using relevant subject headings (controlled 
vocabularies) and search syntax, appropriate to each resource. 
Ovid MEDLINE databases (1 January 2012 onwards) 
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) 
Daily and Ovid MEDLINE(R) 1946 to Present 
1. randomized controlled trial.pt. 
2. controlled clinical trial.pt. 
3. randomi#ed.ti,ab,kf. 
4. (placebo or ((attention or active) adj control*)).ti,ab,kf. 
5. (RCT or ”at random“ or (random* adj3 (administ* or allocat* or assign* or class* or 
control* or determine* or divide* or division or distribut* or expose* or fashion or 
number* or place* or recruit* or split or subsitut* or treat*))).ti,ab,kf. 
6. trial.ti,ab,kf. 
7. ((control* or group* or compar*) adj5 (((care or treatment*) adj2 (usual or standard or 
routine)) or TAU or CAU)).ab. 
8. ((control* or group* or compar*) adj5 (waitlist* or wait* list* or waiting or WLC)).ab.  
9. 9. or/1-8 
10. ANXIETY DISORDERS/ 
11. *ANXIETY/di, pc, px, th 
12. AGORAPHOBIA/ or PANIC DISORDER/ or ANXIETY, SEPARATION/ 
13. PHOBIC DISORDERS/ or PHOBIA, SOCIAL 
14. (agoraphobi* or generali#ed anxiety or GAD or separation anxiety or (social* adj2 (anxi* 
or fear*)) or phobi* or mute? or mutism or school refusal).ti,ab,kf. 
15. ((child* or adolesc* or p?ediatric* or teen* or young* or youth or school) adj1 
anxi*).ti,ab,kf. 
16. anxiety.ab. /freq=3 
17. panic.mp. 
18. (anxiety adj5 (autism or autistic)).ti,ab,kf. 
19. (anxiety ).mp. and (child development disorders, pervasive/px or autism spectrum 
disorder/px or autistic disorder/px)  
20. 20. or/10-19 
21. ((anxi* or phobi* or panic) and (effectiveness or efficacy or evaluat* or intervention or 
program* or train* or treat* or prevent* or therapy or psychotherapy or trial or study) and 
(child* or adolesc* or paediatric* or pediatric* or teen* or young* or youth)).ti. 
22. exp COGNITIVE THERAPY/ 
23. PSYCHOTHERAPY, GROUP/ 
24. FAMILY THERAPY/ or PSYCHODRAMA/ or ROLE PLAYING/ or SENSITIVITY 
TRAINING GROUPS/ 
25. BIBLIOTHERAPY/ 
26. ”EARLY INTERVENTION (Education)“/ 
27. (CBT or CBGT* or iCBT or i-CBT or cCBT or c-CBT or bCBT or b-CBT).ab. 
28. ((cogniti* or behavio*) adj3 (intervention or therap* or psychotherap* or training or 
treatment or technique* or restructur* or defusion)).ti,ab,kf. 
29. (rational emotiv* or (problem* adj2 (focus* or sol*)) or psychoeducat* or role play* or 
schema* or self-control* or self con- trol*).ti,ab,kf. 
30. (((psychotherap* or therap*) adj3 (commitment or acceptance)) or ((self* or stress*) adj3 
(control or analysis or direct* or esteem or help or instruct* or manage*))).ti,ab,kf. 
31. ((attribution* or reattribution*) adj3 (therap* or psychotherap*)).ti,ab,kf. 
32. (mindfulness* or third wave or experiential or (behavio* adj3 (activation or 
modification)) or (thought* adj3 suppress*) or rumi- nation).ti,ab,kf. 
33. ((anxiety adj1 manag*) or confidence building or coping skills or exposure therapy or 
exposure task* or psychoeducat* or psycho- educat* or relaxation or sensitivity training or 
self talk or (social adj2 (skill* or effectiveness))).ti,ab,id,hw. 
34. ((controlling or overcoming) adj2 (anxiety or panic or phobi* or agoraphobi* or 
shyness)).ti,ab,kf. 
35. (Coping Cat or Cool Kids or Coping Koala or (Skills adj Academic adj Social Success) 
or SASS or (Intervention adj Adolescents adj Social Phobia) or IAFS or TAPS).ti,ab,kf. 
36. (child* adj2 (deliver* or focus*) adj2 (intervention* or program* or psychotherap* or 
therap* or train* or treat*)).ti,ab,kf. 
37. ((parent* or guardian*) adj2 (deliver* or focus*) adj2 (intervention* or program* or 
psychotherap* or therap* or train* or treat*)).ti,ab,kf. 
38. ((individually or group or conjoint or family) adj2 (intervention* or program* or 
psychotherap* or therap* or train* or treat*)).ti,ab,kf. 
39. *PSYCHOTHERAPY/mt, st, sn, tu [Methods, Standards, Statistics & Numerical Data, 
Therapeutic Use]  
40. 40. or/22-39 
41. ADOLESCENT/ or CHILD/ or CHILD, PRESCHOOL/ 
42. (child* or adolesc* or paediatr* or pediatr*).hw,jn. 
43. (child* or boy* or girl* or kids or juvenil* or minors or paediatric* or pediatric* or adolesc* 
or preadolesc* or pre-adolesc* or pubert* or pubescen* or prepube* or pre-pube* or teen* or 
(young adj (survivor* or offender* or minorit*)) or youth* or school*).ti,kf. 
44. (child* or adolesc* or paediatr* or pediatr*).ab. /freq=3  
45. 45. or/41-44 
46. (9 and 20 and 40 and 45) or (9 and 21) 
47. (2012* or 2013* or 2014* or 2015* or 2016* or 2017* or 2018*).yr,dp,dt,ep,ez. 
48. 46 and 47 
49. ((OCD or obsessive compulsive or PTSD or posttraumatic stress disorder* or post-
traumatic stress disorder*) not (anxi* or phobi* or agoraphobi* or panic)).ti. 
50. (48 not 49) 
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